Raynaud’s Syndrome News

The severity of Raynaud’s disease is greatest at very low temperatures, but can also increase in hot environments that reach 35°C and above, according to data published in The Lancet Rheumatology.

The FDA has granted orphan drug designation to AISA-021, a fourth-generation calcium channel blocker, for the treatment of systemic sclerosis, according to a press release from Aisa Pharma.

SAN DIEGO — Imaging and symptom rating scales offer physicians ample opportunity to follow patients with suspected myositis and “tease out” fast vs. slow progressors, noted a speaker at the 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — Clinical trials exploring intravenous immunoglobulin and Janus kinase inhibition headline a robust pipeline for idiopathic inflammatory myopathies, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

A fully automated analysis of nailfold images was able to distinguish patients with systemic sclerosis from those with normal capillaries at least as well as human experts, according to data published in Rheumatology.

One of the most common manifestations of Raynaud’s syndrome is noticeable in the extremities through numbness, discoloration and pain during the cold weather months, according to the Raynaud’s Association.

Vasodilator therapy may be underused for Raynaud’s phenomenon and very early systemic sclerosis in U.S. veterans deployed in post-9/11 military operations, according to data published in BMC Rheumatology.

Hour-long, virtual exercise classes that cover Pilates, yoga and tai chi are safe and improved health outcomes in patients with musculoskeletal disease, according to data presented at ACR Convergence 2021.

Healio announced the launch of Rheum and Boards, a quiz-based, online learning resource for rheumatologists, according to a Healio press release.